EGFR and cancer: For instance, epithelial subtypes CMS2 and CMS3 are more dependent on EGFR than CMS1 and CMS4, which was shown before and further supports earlier clinical observations which suggest that CMS4 cancers do not respond to anti-EGFR therapy [41].